These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2527597)

  • 21. [Preclinical evaluation of aromatase inhibitors antitumor activity].
    Auvray P; Bichat F; Genne P
    Bull Cancer; 2000 Dec; 87 Spec No():7-22. PubMed ID: 11250604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The control and biological importance of intratumoural aromatase in breast cancer.
    Dowsett M; Lee K; Macaulay VM; Detre S; Rowlands M; Grimshaw R
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):145-50. PubMed ID: 8603035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
    Brodie AM; Santen RJ
    Crit Rev Oncol Hematol; 1986; 5(4):361-96. PubMed ID: 3094971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretical considerations for the ideal aromatase inhibitor.
    Dowsett M
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S39-44; discussion S73-7. PubMed ID: 9797016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
    Smith IE; Norton A
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S67-71; discussion S73-7. PubMed ID: 9797020
    [No Abstract]   [Full Text] [Related]  

  • 26. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
    Yue W; Brodie AM
    J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
    Harris AL
    Exp Cell Biol; 1985; 53(1):1-8. PubMed ID: 3881300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction to the conference, Aromatase: New Perspectives for Breast Cancer.
    Santen RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3268s. PubMed ID: 7083183
    [No Abstract]   [Full Text] [Related]  

  • 31. [Aromatase inhibitor].
    Stein M
    Med Monatsschr Pharm; 1993 Mar; 16(3):66-7. PubMed ID: 8464387
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical use of aromatase inhibitors in human breast carcinoma.
    Santen RJ
    J Steroid Biochem Mol Biol; 1991; 40(1-3):247-53. PubMed ID: 1835644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
    Raats JI; Falkson G; Falkson HC
    J Clin Oncol; 1992 Jan; 10(1):111-6. PubMed ID: 1530798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
    MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
    Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
    Klepp R; Lønning PE; Kvinnsland S
    Acta Oncol; 1990; 29(4):469-71. PubMed ID: 2143909
    [No Abstract]   [Full Text] [Related]  

  • 36. [Aromatase inhibitors: pharmacological aspects].
    de Crémoux P
    Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer.
    Falkson G; Raats JI; Falkson HC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):161-5. PubMed ID: 1388048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aromatase inhibitors in breast cancer: current and evolving roles.
    Hill J; Moore H
    Cleve Clin J Med; 2002 Jul; 69(7):561-7. PubMed ID: 12109640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
    Dowsett M
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1037-41. PubMed ID: 2149504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
    Nishino Y; Schneider MR; Michna H; el Etreby MF
    J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.